ArticleMMWR. Morbidity and mortality weekly report2026
Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.
Article in MMWR. Morbidity and mortality weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unintentional ingestion of recreational drugs among young children, 2000-2024.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In response to this alert, CDC and the Food and Drug Administration coordinated a nationwide outbreak investigation to characterize the potential poisonings associated with eating Diamond Shruumz microdosing chocolate bars. A case of poisoning was defined as an illness with moderate or major clinical effects (i.e., symptoms) as defined by America's Poison Centers in a person who ate any Diamond Shruumz product or another mushroom-containing chocolate product during January-October 2024. In total, 180 cases were reported in 34 states. Among these, 73 persons were hospitalized, including 38 persons who required intensive care unit (ICU) admission, 29 who required endotracheal intubation, and two deaths. Eating Diamond Shruumz chocolate bars was associated with higher odds of hospitalization (odds ratio [OR] = 3.29; 95% CI = 1.51-7.40), ICU admission (OR = 6.30; 95% CI = 2.17-22.6), seizures (OR = 8.45; 95% CI = 3.00-27.9), and endotracheal intubation (OR = 8.04; 95% CI = 2.24-44.2), compared with eating other mushroom-containing chocolate products. Eating larger amounts of Diamond Shruumz chocolate bars was associated with an increased likelihood of hospitalization, ICU admission, and endotracheal intubation (p-value for trend tests [p-trend] = 0.023, 0.004, and <0.001, respectively). Diamond Shruumz products were recalled, and the public was advised not to eat, sell, or serve any Diamond Shruumz products and to discard any Diamond Shruumz products previously purchased. Testing of some Diamond Shruumz products identified substances present in psychoactive mushrooms, including muscimol, psilocin (a Schedule I controlled substance), kavalactones, and other substances in some, but not all, tested products. Consumers should be aware of the poisoning risk associated with eating Diamond Shruumz products and other mushroom-containing microdosing chocolate products due to variability in ingredient composition, the absence of standardized regulatory oversight for sampling and testing finished products, and the potential toxicity of compounds intended to produce psychoactive effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.